Improving mood and preventing relapse with psychoanalytic psychotherapy and cognitive behaviour therapy

Conditions

Unipolar major depression of moderate to severe severity Mental and Behavioural Disorders Depressive episode

Madison Aitken, Sharon Neufeld, Clement Ma, Ian Goodyer

Journal of Child Psychology and Psychiatry2025-06-09

In Context: Lessons About Adolescent Unipolar Depression From the Improving Mood With Psychoanalytic and Cognitive Therapies Trial

Maria Loades, Nick Midgley, Georgia Tanith Herring, Sally O’Keeffe, Shirley Reynolds et al. (20 authors)

Journal of the American Academy of Child & Adolescent Psychiatry2023-04-2712 citations

10.1016/j.jaac.2023.03.017

How do therapists assess suitability? A qualitative study exploring therapists' judgements of treatment suitability for depressed adolescents

Mikoto Nakajima, Dominika Dykiert, Paul Wilkinson, Nick Midgley

Counselling and Psychotherapy Research2021-08-012 citations

10.1002/capr.12452

Parents' understanding and motivation to take part in a randomized controlled trial in the field of adolescent mental health: a qualitative study.

O'Keeffe S, Weitkamp K, Isaacs D, Target M, Eatough V, Midgley N.

2020-11-239 citations

10.1186/s13063-020-04857-3

Cognitive-behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial.

Goodyer IM, Reynolds S, Barrett B, Byford S, Dubicka B, Hill J, Holland F, Kelvin R, Midgley N, Roberts C, Senior R, Target M, Widmer B, Wilkinson P, Fonagy P.

2017-03-0159 citations

10.3310/hta21120

Cognitive behavioural therapy and short-term psychoanalytical psychotherapy versus a brief psychosocial intervention in adolescents with unipolar major depressive disorder (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled superiority trial.

Goodyer IM, Reynolds S, Barrett B, Byford S, Dubicka B, Hill J, Holland F, Kelvin R, Midgley N, Roberts C, Senior R, Target M, Widmer B, Wilkinson P, Fonagy P.

2016-12-01139 citations

10.1016/s2215-0366(16)30378-9

The experience of adolescents participating in a randomised clinical trial in the field of mental health: a qualitative study

Nick Midgley, Danny Isaacs, Katharina Weitkamp, Mary Target

Trials2016-07-2720 citations

10.1186/s13063-016-1474-2

IMPACT Trial Statistical Analysis Plan

Barrett Barbara, Sarah Byford, Holland Fiona, Roberts Chris

Figshare2016-01-01

10.6084/m9.figshare.3423109.v3

Magnetic resonance imaging of a randomized controlled trial investigating predictors of recovery following psychological treatment in adolescents with moderate to severe unipolar depression: study protocol for Magnetic Resonance-Improving Mood with Psychoanalytic and Cognitive Therapies (MR-IMPACT)

Cindy C. Hagan, Julia M. Graham, Barry Widmer, Rosemary Holt, Cinly Ooi et al. (16 authors)

BMC Psychiatry2013-10-0519 citations

10.1186/1471-244x-13-247

Improving mood with psychoanalytic and cognitive therapies (IMPACT): a pragmatic effectiveness superiority trial to investigate whether specialised psychological treatment reduces the risk for relapse in adolescents with moderate to severe unipolar depression: study protocol for a randomised controlled trial.

Goodyer IM, Tsancheva S, Byford S, Dubicka B, Hill J, Kelvin R, Reynolds S, Roberts C, Senior R, Suckling J, Wilkinson P, Target M, Fonagy P.

2011-07-1374 citations

10.1186/1745-6215-12-175

Interventions

Experimental interventions: 1. Short term psychoanalytic psychotherapy (STPP) (n=180). 30 weekly sessions of treatment

total duration of follow up: 86 weeks from entry, 56 weeks from end of treatment 2. Cognitive behaviour therapy (CBT) (n=180). 20 weekly sessions of treatment

total duration of follow up: 86 weeks from entry, 66 weeks from end of treatment Comparator: Active clinical care (ACC) (n=180). 12 weekly sessions of treatment

total duration of follow up: 74 weeks from entry , 66 weeks from end of treatment All 3 arms will be allowed to prescribe oral fluoxetine 20-40 mg daily. The initial dosage will be 10 mg (as syrup)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Both males and females, age 11 through 17 years 2. Current moderate to severe unipolar major depression (MD) according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria

Exclusion criteria

Exclusion criteria: 1. Generalised learning problems (clinical diagnosis) or a pervasive developmental disorder that results in an inability to complete the questionnaires, or both 2. Pregnant, or currently having sexual relations without reliable contraception 3. Currently taking another medication that may interact with a selective serotonin reuptake inhibitor (SSRI) and unable to stop this medication (uncommon)

Design outcomes

Primary

Measure	Time frame
Persistence of self-reported depressive symptoms at 52 weeks and recurrence of symptoms by 86 weeks. The instrument is the Mood and Feelings Questionnaire (MFQ) consisting of 33 items (range 0-66, higher scores more symptoms, >27 = clinical level of depression).	—

Secondary

Measure	Time frame
1. The Health of the Nation Outcome Scale for Children and Adolescents (HoNOSCA) will be completed by the interviewer (blind to treatment arm) (range 0-68, higher score = greater level of personal impairment) 2. The Children's Depression Rating Scale completed by the clinician treating the patient (range 17-113; higher scores = greater severity) 3. Psychiatric diagnosis: Children's Schedule for Affective Disorders (K-Sads); interviewer based diagnostic measure recording presence or absence of unipolar depression and other psychiatric diagnoses at each assessment point. All secondary outcome measures will be assessed at 0, 6, 12, 36, 52 and 86 weeks.	—

Measure

Time frame

1. The Health of the Nation Outcome Scale for Children and Adolescents (HoNOSCA) will be completed by the interviewer (blind to treatment arm) (range 0-68, higher score = greater level of personal impairment) 2. The Children's Depression Rating Scale completed by the clinician treating the patient (range 17-113; higher scores = greater severity) 3. Psychiatric diagnosis: Children's Schedule for Affective Disorders (K-Sads); interviewer based diagnostic measure recording presence or absence of unipolar depression and other psychiatric diagnoses at each assessment point. All secondary outcome measures will be assessed at 0, 6, 12, 36, 52 and 86 weeks.

—

Countries

England, United Kingdom

Outcome results

None listed